CPIC 2026 | Nanobody Drug R&D Session Agenda Released
May 19,2026
Small in size, powerful in function, nanobodies are reshaping the R&D paradigm of biopharmaceuticals. The full agenda of the Nanobody Drug R&D Session, co organized by Biointron, is unveiled today.
This session brings together pioneers in the nanobody sector to systematically dissect key links across the entire nanobody drug development chain — from hit discovery and engineering design, to druggability evaluation and large scale manufacturing. Join industry trailblazers in Shanghai, July 22–24, to discuss the future of nanobodies.
Special Session Agenda
Co-organizer: BioEngine
Opening Remarks
Changchun Zha：Chairman, Biointron
Progress of Nanobody‑based Therapeutics & Applications in ADCs
Haikun Shi: Founder & Chairman, Kunyu Biotech
Development of Nanobody Therapeutics for Diabetic Nephropathy
Jiajun Fan: Director & Principal Investigator, Institute of Biotech Pharmaceuticals, Quzhou Fuda Biomedical Innovation Institute; Shanghai Rising Star Young Scientist
Dual Epitope Nanobodies for Acute Disease Therapy Strategies
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
Applications of Diverse Screening Platforms in Nanobody Discovery
Lei Shi: Senior Vice President, Biointron
Roundtable: Challenges and Future of Next‑Generation Antibody Drugs
Moderator: Haikun Shi: Founder & Chairman, Kunyu Biotech
Shuqing Chen: Professor & Doctoral Supervisor, College of Pharmaceutical Sciences, Zhejiang University; Founder & Chairman, Neoantigen
Jun Wang: General Manager,Jushi Biotech,CSPC Pharmaceutical Group
Tao Xu: Founder & CEO, SmartNuclide
Jing Huang: COO & CBO, Novamab
Mingyue Huang: Founder, Chairman & CEO, BiyoPharma
Follow or Contact Us
Follow the TONACEA Official WeChat Account and scan the QR code to register. Stay updated with the latest conference news.
Public Account QR Code
Registration QR Code
Conference Service Hotline
© 2026 TONACEA (Shanghai) Technology Development Co., Ltd. All rights reserved. All rights reserved.
